Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Frontage HoldingsFGHQF 54 Debt-to-EBITDA is 6.50 as of Dec. 2025, which is 460% above its 10-year median of 1.16. GuruFocus rates FGHQF with a GF Score™ of 54/100 and a GF Value™ of $0.23 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 297 Biotechnology companies, Frontage Holdings ranks worse than 83.16% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Frontage Holdings's Debt-to-EBITDA or its related term are showing as below:
FGHQF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.47 Med: 1.16 Max: 6.64
Current: 6.64
During the past 10 years, the highest Debt-to-EBITDA Ratio of Frontage Holdings was 6.64. The lowest was 0.47. And the median was 1.16.
FGHQF's Debt-to-EBITDA is ranked worse than 83.16% of 297
companies
in the Biotechnology industry
Industry Median: 1.16
vs FGHQF: 6.64
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Frontage Holdings Debt-to-EBITDA Related Terms
Frontage Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Frontage Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FGHQF vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Frontage Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Frontage Holdings (FGHQF) has a Debt-to-EBITDA of 6.50 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Frontage Holdings. This is 460% above median its historical median of 1.16. Over the past decade, Frontage Holdings' Debt-to-EBITDA has ranged from 0.47 to 6.64. According to the industry distribution chart, Frontage Holdings ranks #247 out of 297 companies in the Biotechnology industry, placing it in the top 83.2%.
Is Frontage Holdings' Debt-to-EBITDA too high?
Frontage Holdings' current Debt-to-EBITDA of 6.50 is 460% above median its 10-year median of 1.16. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 6.64. The Biotechnology industry median Debt-to-EBITDA is 1.16. Frontage Holdings' value of 6.50 is 460.3% above this industry median. Based on the distribution chart, Frontage Holdings ranks #247 out of 297 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Frontage Holdings has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontage Holdings' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Frontage Holdings ranks #247 out of 297 companies for Debt-to-EBITDA. This places Frontage Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.16. Frontage Holdings' value of 6.50 is 460.3% above this benchmark. Historically, Frontage Holdings' own Debt-to-EBITDA has ranged from 0.47 to 6.64 over the past decade. While the company's 10-year median is 1.16 vs. the industry median of 1.16, Frontage Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.16, based on 297 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Frontage Holdings's current Debt-to-EBITDA of 6.50 is 460.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Frontage Holdings. For the Biotechnology industry, the median Debt-to-EBITDA is 1.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontage Holdings's current Debt-to-EBITDA is 6.50, which is 460% above median its own 10-year median of 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontage Holdings stock overvalued right now?
Based on GuruFocus' analysis, Frontage Holdings (FGHQF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.23, compared to a current price of $0.15 — trading 34.8% below its estimated fair value. The current Debt-to-EBITDA is 6.50, which is 460% above median its 10-year median of 1.16 and 460.3% above the Biotechnology industry median of 1.16. Frontage Holdings' overall GF Score™ is 54/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Frontage Holdings (FGHQF), the current Debt-to-EBITDA is 6.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontage Holdings (FGHQF) Overvalued in 2026?
Based on GuruFocus' analysis, Frontage Holdings stock appears to be undervalued.
The current stock price of $0.15 is trading 34.8% below its estimated GF Value™ of $0.23.
GuruFocus considers Frontage Holdings to be Significantly Undervalued.
Key valuation signals for FGHQF:
Debt-to-EBITDA: 6.50 (460% above median its 10-year median of 1.16)
GF Value™: $0.23 vs. price of $0.15 (34.8% below fair value)
Industry Position: 460.3% above the Biotechnology median (#247 of 297)
No single metric tells the full story. See the FGHQF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
54GF Score
Get the complete analysis for FGHQF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FGHQF has been successfully added to your 
